Options for modulation of drug resistance in ovarian cancer

被引:18
作者
Arts, HJG
Van der Zee, AGJ
De Jong, S
De Vries, EGE
机构
[1] Univ Groningen Hosp, Dept Med Oncol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen Hosp, Dept Gynaecol Oncol, NL-9700 RB Groningen, Netherlands
关键词
drug resistance; ovarian cancer; review;
D O I
10.1046/j.1525-1438.2000.99511.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The objective of this paper is to present an update of mechanisms responsible for drug resistance in ovarian cancer and the possible therapeutic options to modulate this resistance using literature review with emphasis on data acquired in studies comprising ovarian tumor samples. The classic concepts on resistance in ovarian cancer, namely platinum and multidrug resistance, are briefly discussed, followed by a description of more recent insights concerning the role of apoptosis in the development of chemoresistance. A wide variety of mechanisms may be responsible for drug resistance in ovarian cancer. However, a growing body of evidence indicates that defects in the intra- and extracellular apoptotic pathways are an important cause of resistance to cytotoxic agents which opens several new treatment strategies.
引用
收藏
页码:47 / 52
页数:6
相关论文
共 42 条
  • [1] Arts HJG, 1999, CLIN CANCER RES, V5, P2798
  • [2] Bookman MA, 1998, SEMIN ONCOL, V25, P381
  • [3] Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?
    Borst, P
    Kool, M
    Evers, R
    [J]. SEMINARS IN CANCER BIOLOGY, 1997, 8 (03) : 205 - 213
  • [4] BOS AME, 1999, IN PRESS P AM ASS CL
  • [5] Chemotherapy resistance in ovarian cancer: New molecular perspectives
    Coukos, G
    Rubin, SC
    [J]. OBSTETRICS AND GYNECOLOGY, 1998, 91 (05) : 783 - 792
  • [6] ERCC1 AND ERCC2 EXPRESSION IN MALIGNANT-TISSUES FROM OVARIAN-CANCER PATIENTS
    DABHOLKAR, M
    BOSTICKBRUTON, F
    WEBER, C
    BOHR, VA
    EGWUAGU, C
    REED, E
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (19) : 1512 - 1517
  • [7] Gratas C, 1998, CANCER RES, V58, P2057
  • [8] Apoptosis and chemotherapy resistance
    Hickman, JA
    [J]. EUROPEAN JOURNAL OF CANCER, 1996, 32A (06) : 921 - 926
  • [9] Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs
    Izquierdo, MA
    Scheffer, GL
    Flens, MJ
    Shoemaker, RH
    Rome, LH
    Scheper, RJ
    [J]. CYTOTECHNOLOGY, 1996, 19 (03) : 191 - 197
  • [10] IZQUIERDO MA, 1995, JNCI-J NATL CANCER I, V87, P1230